Home
Login Register
Vicplas Intl    Last:0.078    -0.001

Construction Material & Bio-Medical Outsourcing

 Post Reply 1721-1738 of 1738
 
Wind22i
    29-Jan-2020 21:08  
Contact    Quote!
How to play this...no volume at all...
Today got 1 big seller come out at 12c.... 600k units...maybe thats joseph....haha
 
 
wiltay
    29-Jan-2020 16:59  
Contact    Quote!
Thks for the sharing 🤔

josephyeo      ( Date: 29-Jan-2020 15:47) Posted:

As can be seen below, the company is well positioned in China n in the relevant segments also, that is:
Airway Management n Respiratory segment
.

Demand for Vicplas products are likely to surge given the current health issues in Wuhan.


A quote from company' s annual report:


The design, development and manufacture of sterile and non-sterile medical devices through our wholly-owned subsidiaries,
- Forefront Medical Technology (Pte) Ltd and
- Forefront Medical Investment Pte. Ltd. in Singapore
- Forefront (Xiamen) Medical Devices Co., Ltd and
- Forefront Medical Technology (Jiangsu) Co., Ltd in China
- and 81% owned subsidiary, XentiQ (Pte.) Ltd. in Singapore.

A quote from 1st half financial report:

full medical devices for an increasing number of medical industry segments such as
- Airway Management,
- Respiratory, Endoscopy,
- Drug Delivery and
- Vascular.
Also, the segment has shown substantial depth of experience and expertise that gives its global customers
the confidence to place orders with it for the manufacturing of their medical devices.

Just sharing. Dyodd

 
 
wiltay
    29-Jan-2020 16:58  
Contact    Quote!
This two counters maybe good for quick profit.. don't will last long boh?

Casilb      ( Date: 29-Jan-2020 16:50) Posted:

If good will already run like ug healthcare and medtecs liao lo

wiltay      ( Date: 29-Jan-2020 16:48) Posted:

Sound good.. but not moving at all 🙄


 

 
Casilb
    29-Jan-2020 16:50  
Contact    Quote!
If good will already run like ug healthcare and medtecs liao lo

wiltay      ( Date: 29-Jan-2020 16:48) Posted:

Sound good.. but not moving at all 🙄

josephyeo      ( Date: 29-Jan-2020 15:47) Posted:

As can be seen below, the company is well positioned in China n in the relevant segments also, that is:
Airway Management n Respiratory segment
.

Demand for Vicplas products are likely to surge given the current health issues in Wuhan.


A quote from company' s annual report:


The design, development and manufacture of sterile and non-sterile medical devices through our wholly-owned subsidiaries,
- Forefront Medical Technology (Pte) Ltd and
- Forefront Medical Investment Pte. Ltd. in Singapore
- Forefront (Xiamen) Medical Devices Co., Ltd and
- Forefront Medical Technology (Jiangsu) Co., Ltd in China
- and 81% owned subsidiary, XentiQ (Pte.) Ltd. in Singapore.

A quote from 1st half financial report:

full medical devices for an increasing number of medical industry segments such as
- Airway Management,
- Respiratory, Endoscopy,
- Drug Delivery and
- Vascular.
Also, the segment has shown substantial depth of experience and expertise that gives its global customers
the confidence to place orders with it for the manufacturing of their medical devices.

Just sharing. Dyodd


 
 
wiltay
    29-Jan-2020 16:48  
Contact    Quote!
Sound good.. but not moving at all 🙄

josephyeo      ( Date: 29-Jan-2020 15:47) Posted:

As can be seen below, the company is well positioned in China n in the relevant segments also, that is:
Airway Management n Respiratory segment
.

Demand for Vicplas products are likely to surge given the current health issues in Wuhan.


A quote from company' s annual report:


The design, development and manufacture of sterile and non-sterile medical devices through our wholly-owned subsidiaries,
- Forefront Medical Technology (Pte) Ltd and
- Forefront Medical Investment Pte. Ltd. in Singapore
- Forefront (Xiamen) Medical Devices Co., Ltd and
- Forefront Medical Technology (Jiangsu) Co., Ltd in China
- and 81% owned subsidiary, XentiQ (Pte.) Ltd. in Singapore.

A quote from 1st half financial report:

full medical devices for an increasing number of medical industry segments such as
- Airway Management,
- Respiratory, Endoscopy,
- Drug Delivery and
- Vascular.
Also, the segment has shown substantial depth of experience and expertise that gives its global customers
the confidence to place orders with it for the manufacturing of their medical devices.

Just sharing. Dyodd

 
 
wiltay
    29-Jan-2020 16:45  
Contact    Quote!
Counter just sit quietly give good dividend 😴 😴 😴 😴 😴
 

 
Casilb
    29-Jan-2020 16:37  
Contact    Quote!
No volume and people playing this lah 😴 😴
 
 
josephyeo
    29-Jan-2020 15:47  
Contact    Quote!
As can be seen below, the company is well positioned in China n in the relevant segments also, that is:
Airway Management n Respiratory segment
.

Demand for Vicplas products are likely to surge given the current health issues in Wuhan.


A quote from company' s annual report:


The design, development and manufacture of sterile and non-sterile medical devices through our wholly-owned subsidiaries,
- Forefront Medical Technology (Pte) Ltd and
- Forefront Medical Investment Pte. Ltd. in Singapore
- Forefront (Xiamen) Medical Devices Co., Ltd and
- Forefront Medical Technology (Jiangsu) Co., Ltd in China
- and 81% owned subsidiary, XentiQ (Pte.) Ltd. in Singapore.

A quote from 1st half financial report:

full medical devices for an increasing number of medical industry segments such as
- Airway Management,
- Respiratory, Endoscopy,
- Drug Delivery and
- Vascular.
Also, the segment has shown substantial depth of experience and expertise that gives its global customers
the confidence to place orders with it for the manufacturing of their medical devices.

Just sharing. Dyodd
 
 
Casilb
    29-Jan-2020 15:43  
Contact    Quote!
Probably wont move bah not really related to the virus also

wiltay      ( Date: 29-Jan-2020 12:28) Posted:

Many medtech companies counter up.. this counter still half sleep. 🙄 😴

 
 
wiltay
    29-Jan-2020 12:28  
Contact    Quote!
Many medtech companies counter up.. this counter still half sleep. 🙄 😴
 

 
superstartup
    16-Oct-2019 14:47  
Contact    Quote!
This director good leh.
Throw $.

==========

The Board of Directors of Vicplas International Ltd (the Company) wishes to announce that on 9 October 2019 the Company has allotted and issued 1,250,000 ordinary shares (the New Shares) in the capital of the Company to a director at the exercise price of S$0.115 each pursuant to the exercise of options previously granted under the Vicplas International Share Option Plan. The New Shares are listed and quoted on the Singapore Exchange Securities Trading Limited on 11 October 2019. The New Shares issued rank pari passu in all respects with the existing ordinary shares of the Company in issue. Following the allotment and issue of New Shares, the number of issued and paid-up shares in the capital of the Company has increased to 507,677,699 ordinary shares (including treasury shares) and the issued and paid-up share capital has increased to S$50,605,184. BY ORDER OF THE BOARD Cheng Liang Group Chief Executive Officer Singapore, 11 October 2019 
 
 
wiltay
    10-Mar-2016 20:11  
Contact    Quote!


Business growing but not many people investing?  surprise 
 
 
wiltay
    09-Mar-2016 20:14  
Contact    Quote!


Revenue for the Group increased to S$40.2 million for the six months ended 31 Jan 2016 (" 1H FY2016" ) from S$37.6 million for the six months ended 31

Jan 2015 (" 1H FY2015" ). As compared to the previous corresponding period, revenue of the medical devices segment increased by S$4.2 million due to an

increase in orders from customers. Revenue for the pipes and pipe fittings segment decreased by S$1.6 million due to the slowdown in the construction

industry in Singapore. yeswink

 

 
 
 
wiltay
    07-Oct-2015 15:28  
Contact    Quote!


What!!! really nobody put $$$ in this counter. sad
 
 
wiltay
    01-Oct-2015 11:28  
Contact    Quote!
Anyone investing in this?
 

 
wiltay
    28-Sep-2015 22:11  
Contact    Quote!

Vicplas International Ltd Reports Unaudited Group Earnings Results for the Year Ended July 31, 2015 Announces Final and Special Dividend for Fiscal Year 2015



Source: Singapore Stock exchange
Type: Announcements of Earnings, Dividend Increases, Special Dividend Announced
From: 22/Sep/2015
Vicplas International Ltd. reported unaudited group earnings results for the year ended July 31, 2015. For the year, the company' s revenue was SGD 74,100,000 compared to SGD 63,263,000 a year ago. Profit before tax was SGD 7,137,000 compared to loss before tax of SGD 2,825,000 a year ago. Profit for the year attributable to the owners of the company was SGD 5,772,000 or 1.20 cents per fully diluted share, due to the higher profits of the pipes and pipe fittings segment exceeding the reduced losses of the medical devices segment, compared to loss for the year attributable to the owners of the company of SGD 4,068,000 0.87 cents per fully diluted share a year ago. Net cash from operating activities was SGD 7,885,000 compared to net cash used in operating activities of SGD 7,071,000 a year ago, mainly due to the improved performance of the Group. Purchase of property, plant and equipment was SGD 2,843,000 compared to SGD 3,472,000 a year ago. The company also announced final dividend of SGD 0.005 per ordinary share (one-tier tax exempt) and special dividend of SGD 0.0025 per ordinary share (one-tier tax exempt). The Directors are proposing to apply the Scrip Dividend Scheme to the final and special dividends for fiscal year 2015. No dividend was declared for the corresponding period of the immediately preceding financial year. laugh
 
 
wiltay
    20-Mar-2015 10:04  
Contact    Quote!


Revenue for the Group increased to S$37.6 million for the six months ended 31 Jan 2015 (" 1H FY2015" ) from S$30.1 million for the six months ended 31

Jan 2014 (" 1H FY2014" ). As compared to the previous corresponding period, revenue of the medical device segment increased by S$1.9 million due to an

increase in orders from customers. Revenue for the pipes and pipe fittings segment increased by S$5.6 million from S$19.9 million in 1H FY2014 due to

the marketing to construction and civil engineering sectors in Singapore, broadening of the customer base and an increase in product offerings.
 
 
upnowhere
    09-May-2014 20:22  
Contact    Quote!


This counter just  like a sleep king for ages no
 
Important: Please read our Terms and Conditions and Privacy Policy .